Objectives: Identify pediatric heart transplant (HT) recipients with heterotaxy and other complex arrangements of cardiac situs (heterotaxy/situs anomaly) and compare mortality, morbidities, length of stay (LOS), and costs to recipients with congenital heart disease without heterotaxy/situs anomaly.
For heterotaxy recipients (vs. non-heterotaxy recipients
Increased mortality, morbidities, and costs for heart transplant recipients with heterotaxy.
Central Message
Heart transplantation in patients with heterotaxy/cardiac situs anomalies is associated with increased mortality, early morbidities, and higher care costs compared with transplantation for other congenital heart diseases.
Perspective
Children with heterotaxy who undergo heart transplantation are understudied. We found they have increased mortality, early morbidities (including need for dialysis, cardiac reoperation, and vascular intervention), and care costs relative to nonheterotaxy transplant recipients. Anticipation of these features may aid decision making around transplant candidacy and during postoperative care.
See Editorial Commentary page 741. Heterotaxy is characterized by organ laterality defects and complex congenital heart disease (CHD). 1 Survival has historically been poor compared with other forms of CHD, particularly early after cardiac surgery due to technical difficulties posed by anomalies of situs. 2, 3 Heart transplantation (HT) has been reported for patients with heterotaxy in case reports 4 and single center series. 5 However, due to the lack of an indicator variable in transplant registries, there has been no large, multicenter analysis of outcomes and complications for recipient with heterotaxy; thus, limited information is available to guide providers and patients.
We used a novel linkage between the Scientific Registry of Transplant Recipients (SRTR) and the Pediatric Health Information System (PHIS) databases to describe survival, length of stay (LOS), hospitalization costs, and morbidities following HT for children and young adults with heterotaxy and other complex arrangements of cardiac situs (ie, heterotaxy/sinus anomaly). We hypothesized that HT recipients with heterotaxy/situs anomaly would have increased early post-HT mortality and greater LOS and hospital costs from HT to discharge compared with recipients with CHD in the absence of heterotaxy/situs anomaly. Following the early post-HT phase, we hypothesized that survival for heterotaxy/situs anomaly recipients would be similar to nonheterotaxy/situs anomaly recipients. We did not specify hypothesis regarding morbidities given the multiple morbidities that were explored.
METHODS Database Linkage and Patient Selection
Database linkage at the patient level used indirect identifiers and was performed and validated as previously described. 6 SRTR includes data on all donors, wait-listed candidates, and recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration of the US Department of Health and Human Services provides oversight to the activities of the Organ Procurement and Transplantation Network and SRTR contractors. 7 PHIS is an administrative database of International Classification of Diseases ninth and 10th edition (ICD-9/10) codes, hospital charges, and resource use for hospital-based patient encounters across>45 US children's hospitals. 8 We mapped ICD-10 to ICD-9 using the Agency for Healthcare Research and Quality MapIT Tool 9 (Table E1 ). The linked database contained 3062 records of transplant and follow-up data from November 2001 to November 2016. After exclusions for retransplantation (n ¼ 189) and missing/non-CHD diagnosis (n ¼ 1433), analysis was performed on patients who underwent primary HT for CHD (n ¼ 1440 [47%]). Heterotaxy/situs anomaly (n ¼ 186) was defined as any patient with an SRTR diagnosis of CHD plus !1 of the following ICD-9/10 codes within their entire PHIS record: 759.3/Q89.3 (situs inversus); 759.0/ Q89.01, Q89.09 (polysplenia/asplenia); or 746.87/Q24.0 (dextrocardia). Primary HT recipients not meeting these criteria formed the comparison group of CHD recipients without heterotaxy/situs anomaly (n ¼ 1254).
Data Sources and Collection
From SRTR we collected recipient sex, race, diagnosis (CHD/non-CHD), history of sternotomy and/or thoracic surgery for CHD, and HT date; age, waitlist urgency status, patient location (intensive care unit [ICU]/in-hospital/outside hospital), and use of inotropic support, mechanical ventilation, ventricular assist device (VAD), and extracorporeal membrane oxygenation (ECMO) at HT; dialysis while listed; pre-HT serum creatinine; donor-specific cross-match (DSXM); ischemic time; and donor and recipient organ procurement organizations (OPOs). The following were collected from SRTR: treatment for infection or acute rejection, cardiac reoperation, and posttransplant dialysis during the HT admission; latest vital status (ie, alive/deceased/retransplanted) with date; cause of death; infection or rejection requiring rehospitalization; and occurrence of posttransplant lymphoproliferative disease (PTLD) and coronary allograft vasculopathy (CAV).
PHIS data were used to characterize the underlying CHD phenotypes in the study population; characterize surgeries, procedures, and infections that occurred after HT during the HT hospitalization; and quantify inpatient costs and the durations of post-HT mechanical ventilation, ICU LOS, and hospital LOS. All costs were adjusted for inflation to 2016 US dollars using the medical component of the consumer price index and were calculated from charges using hospital and year-specific cost-to-charge ratios.
To characterize the spectrum of underlying CHD phenotypes we identified the following cardiovascular morphology ICD-9/10 diagnosis codes applied during the transplant hospitalization in PHIS: ICD-9 codes beginning with 745 (Bulbus cordis anomalies and anomalies of cardiac septal closure), 746 (Other congenital anomalies of the heart), and 747 (Other congenital anomalies of the circulatory system), and ICD-10 codes Q20-Q28 (Congenital malformations of the circulatory system). Similarly, cardiovascular surgeries and procedures that occurred after HT during the transplant hospitalization were assessed by identifying ICD-9 procedure codes that begin with 35, 36, 37, 38 , and 39 (Operations on the cardiovascular system) and ICD-10 procedure codes beginning with 02 (Heart and great vessels). To explore differences in encapsulated bacterial infections, we identified the relevant ICD-9/10 diagnosis codes assigned during the transplant admission (Table E2) . Duplicated codes were only counted once per subject.
Statistical Analysis
Data are described as median (interquartile range) or count (%), as appropriate. Odds and hazard ratios are reported with 95% confidence intervals (CIs). Categorical data were compared using the c 2 or Fisher exact test, as appropriate. Continuous data were compared using the Wilcoxon rank-sum test. Post-HT procedures were compared between the groups by calculating the odds ratio (OR) of procedure with Fisher exact 95% CI. Univariate survival was assessed with the Kaplan-Meier estimator and compared using the log-rank test. Survival curves were truncated when approximately 10% of patients were left at-risk. Because death competes with postdischarge infection, rejection, PTLD, and CAV, each of these outcomes was analyzed by competing-risks regression 10 in which the competing risk of death/retransplantation was considered. Significant differences in outcomes between the groups in univariate comparison were adjusted for covariates using multivariable Cox proportional hazards, logistic, and linear regression models, as appropriate. To build the models the following covariates were tested for a univariate effect on outcome: race, age, year of HT, prior sternotomy and/or prior CHD surgery, dialysis on waitlist, DSXM result, waitlist urgency status, patient location, inotropic support, mechanical ventilation, VAD, and ECMO at HT. For analysis of post-HT renal failure requiring dialysis, we included pre-HT dialysis, glomerular filtration rate (eGFR) <40 mL/min/1.73 m 2 , and ischemic time >3.5 hours. eGFR was estimated using the modified Schwartz formula, 11 capped at 200 mL/min/1.73 m 2 . Procurement distance was estimated by computing the geodesic distance between donor and recipient OPO ZIP codes, 12 and used as a covariate in linear regression analysis of ischemic time between the groups. Covariates with P values .1 in univariate comparisons were included in the multivariable model with the main variable of interest. Covariates with Wald test P>.1 in the full multivariable models were then dropped from the analysis to produce final models. The proportional hazards assumption was assessed for Cox models by visualization of log-log survival plots and with regression of the scaled Schoenfeld residuals on the identity function of time. 13 Covariates that violated the proportional hazards assumption were stratified in Cox models. Presence of significant interaction terms were assessed with the likelihood-ratio test.
Missing data were compared across groups (Table E3 ). For pre-HT VAD and dialysis, missing data were rare (<3%) and imputed as ''no.'' For DSXM, prior sternotomy and/or prior CHD repair, and prior univentricular CHD repair, missing data were assumed to be randomly missing and imputed using multiple imputation. Subjects with missing outcomes data were excluded for analysis of that outcome.
Sensitivity Analyses
To address potential misclassification based on the nonspecificity of the dextrocardia and situs inversus ICD codes, subjects were reclassified using stricter inclusion criteria of only polysplenia/asplenia ICD codes and survival analysis was repeated. To address possible misspecification of model variables, we modified all Cox models to include additional user-selected, clinically relevant covariates. Finally, to address the potential for bias from inadequate/incomplete selection of model covariates, we performed propensity score matching in which the probability of a subject being classified into the heterotaxy/situs anomaly group was determined by logistic regression on characteristics listed in Table E4 . Missing data were coded as a categorical dummy variable for each covariate, allowing patients with missing data to be matched. Matching was 1:2 using a matching caliper of one-fifth the standard deviation of the logit of the propensity scores. Covariate balance was assessed through calculation of the standardized mean bias, with values > 0.2 considered significant.
All analyses were performed using Stata version 13 (StataCorp, College Station, Tex). This research was approved by the Vanderbilt University and University of Pittsburgh Institutional Review Boards, PHIS, and SRTR. See highlights of the study in Video 1.
RESULTS

Group Characteristics
Group characteristics at transplant are shown in Table  1 . The heterotaxy/situs anomaly group was older (median age, 5.1 years vs 1.6 years; P < .001) and more often African American, Asian, Hispanic, or ''other'' nonwhite (54% vs 32%; P < .001). A lower proportion in the heterotaxy/situs anomaly group had reduced eGFR (3% vs 9%; P ¼ .004). We found no other significant differences between groups, including proportion with prior sternotomy and/or surgery for CHD (76% vs 68%; P ¼ .196). There were no significant differences in missing data between groups (Table E3) .
ICD codes used to define the heterotaxy/situs anomaly group were distributed as follows: dextrocardia ( Table E5 demonstrates the spectrum of underlying CHD phenotypes described by ICD codes. The heterotaxy/situs anomaly group was enriched for codes for endocardial cushion defect, common ventricle, pulmonary outflow tract obstruction, disorders of pulmonary and systemic venous return, truncus abnormalities, and conduction abnormalities. The nonheterotaxy/situs anomaly CHD group was enriched for hypoplastic left heart syndrome, coronary artery anomalies, and secundum atrial septal defects. See Table E5 for full data. 
Survival After Transplant
Median follow-up was 3.03 years (range, 1.00-6.91 years). The heterotaxy/situs anomaly group demonstrated inferior post-HT survival in unadjusted analysis (P ¼ .002) (Figure 1, A) . Univariable and multivariable Cox model specifications are shown in Tables E6 and E7 . After adjustment for African-American race, calendar year of HT, and pre-HT ECMO, heterotaxy/situs anomaly was associated with an increased mortality compared with nonheterotaxy/situs anomaly CHD (hazard ratio [HR], 1.58; 95% CI, 1.19-2.09; P ¼ .002). These findings persisted amongst 6-month post-HT survivors in unadjusted (P ¼ .007) (Figure 1 , B) and adjusted analyses (HR, 1.86; 95% CI, 1.09-3.16; P ¼ .021; adjusted for age and African-American race). There were no significant differences in cause of death between the groups (Table 2) or in the cumulative incidences of PTLD, CAV, admission for infection, or admission for rejection between the groups (Figure 2, A-D) . Of note, 2 recipients (1%) in the heterotaxy/situs anomaly group and 30 (2%) in the nonheterotaxy/situs anomaly group underwent retransplantation during the observation period. Data are presented as n (%) or median (interquartile range). CHD, Congenital heart disease; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; VAD, ventricular assist device; HT, heart transplant; ECMO, extracorporeal membrane oxygenation; DXSM, donor-specific crossmatch; OPO, organ procurement organization. *Continuous data compared with rank-sum test, binary outcomes compared using c 2 test of proportions. yMissing data present; see Table E3 for number and proportion missing from each group for each of these variables. zTested across all groups.
Posttransplant Complications, LOS, and Cost
Perioperative complications analyzed from SRTR are shown in Table 3 . Univariable and multivariable logistic model specifications are shown in Tables E8 and E9 . Cardiac reoperation (adjusted OR, 1.91; P ¼ .010) and renal failure requiring dialysis (adjusted OR, 2.58; P ¼ .001) were increased among heterotaxy/situs anomaly recipients prior to discharge following HT. Heterotaxy/situs anomaly recipients were more commonly treated for infection before discharge following HT (adjusted OR, 1.54; P ¼ .015); however, we found no difference in PHIS-recorded encapsulated bacterial infection ICD codes between the groups (2.9% vs 2.3%; P ¼ .638). There were similar proportions with acute rejection during the HT hospitalization (17% each; P ¼ .916).
As shown in Table 4 , data from PHIS support increased complications between HT and hospital discharge. ICD procedure codes for venous catheterization (OR, 1.65; P ¼ .010), insertion of nondrug-eluting peripheral (noncoronary) vessel stent(s) (OR, 2.94; P ¼ .016), and hemodialysis (OR, 2.67; P ¼ .013) were more common among heterotaxy/situs anomaly recipients. We also found greater duration of mechanical ventilation after HT for heterotaxy/ situs anomaly recipients (median 5 vs 4 days; P ¼ .039) ( Table 5) , with a greater proportion of heterotaxy/situs anomaly recipients requiring mechanical ventilation for >1 week after HT (44 vs 36%; adjusted OR, 1.70; 95% CI, 1.20-2.40; P ¼ .003) ( Log-rank P = .007 B FIGURE 1. A, Survival after heart transplantation with heterotaxy/situs anomaly. Univariable Kaplan-Meier estimator showing that patients with heterotaxy/situs anomaly (Het) (red) have inferior survival after heart transplantation compared with other patients with congenital heart disease (CHD) in the absence of heterotaxy/situs anomalies (Non-Het) (blue). The curves sharply diverge early after transplant (approximately 6-12 mo) and continue to diverge more gradually thereafter, consistent with survival differences between the groups both early and later after transplantation. B, Survival after heart transplantation with Het, conditional upon survival to 6-months after transplantation. Univariable Kaplan-Meier estimator showing that among 6-month postheart transplant survivors, patients with Het (red) have decreased survival compared with patients with CHD in Non-Het (blue). This analysis confirms a survival difference between the groups occurring outside the perioperative phase. (Tables E11 and E12 ).
Sensitivity Analyses
After forcing clinically important variables of age and history of prior univentricular repair into the primary outcome Cox model, we still observed increased mortality among heterotaxy/situs anomaly recipients (HR, 1.52; 95% CI, 1.13-2.03; P ¼ .005; adjusted for AfricanAmerican race, year of HT, pre-HT ECMO, age, and history of prior univentricular repair). After reclassification of patients with heterotaxy based solely on ICD codes for polysplenia/asplenia, heterotaxy/situs anomaly remained an independent predictor of mortality (HR, 1.51; 95% CI, 1.04-2.21; P ¼ .032) adjusted for African-American race, year of HT, and ECMO at HT ( Figure E1 ). In propensity score-matched cohorts, 186 recipients with heterotaxy/situs anomaly were matched to 368 non-heterotaxy/situs anomaly CHD HT recipients (Table E4 and Figure E2 ). Heterotaxy/situs anomaly was associated with increased mortality (HR, 1.53; 95% CI, 1.09-2.16; P ¼ .015). Values are presented as n (%). CI, Confidence interval; HT, heart transplant. *Infection during HT admission adjusted for: year, pre-HT extracorporeal membrane oxygenation, pre-HT mechanical ventilation, home location at HT, positive donor-specific cross-match, and history of prior univentricular CHD repair. yAdjusted for patient race, ventricular assist device, and mechanical ventilation pre-HT. zAdjusted for pre-HT dialysis, estimated glomerular filtration rate<40 mL/min/1.73 m 2 , ischemic time>3.5 hours, extracorporeal membrane oxygenation, ICU location at HT, and female race. xAdjusted for mechanical ventilation pre-HT, pre-HT extracorporeal membrane oxygenation, and age. Source data: Scientific Registry of Transplant Recipients. Values for heterotaxy and nonheterotaxy congenital heart disease are presented as n (%). ICD-9, International Classification of Diseases ninth edition. *ICD-10 procedure codes were translated to ICD-9. yFisher exact test. Source data: Pediatric Health Information System database.
DISCUSSION Significance of Main Findings
We provide the most extensive report of post-HT outcomes for children with heterotaxy/situs anomaly from a large sample of US pediatric HT centers (Figure 3 ). To date, knowledge about HT outcomes for heterotaxy patients has been limited to anecdotal experience, case reports, and single center series. Jacobs and colleagues 14 reported suboptimal outcomes in 5 HT recipients with heterotaxy, whereas Cohen and colleagues 15 reported survival to 32 and 33 months for 2 HT recipients with heterotaxy. In the largest previous report, 29 pediatric HT recipients with heterotaxy at a single-center showed no difference in survival relative to controls with dilated cardiomyopathy. 5 Our main findings are that patients with heterotaxy/situs anomaly have decreased survival after HT and accrue greater costs for care with longer LOS after HT relative to other recipients who underwent HT for CHD (Figure 3) . We also observed increased early post-HT morbidities, including longer ischemic times, increased prevalences of cardiac reoperation, catheterization, peripheral vessel stenting, and renal failure among heterotaxy/situs anomaly recipients. Although associations do not imply causality, these increased morbidities could explain greater mortality and resource use among heterotaxy/situs anomaly recipients.
Not well explained is the late survival difference we observed. Although the heterotaxy/situs anomaly group was older and disproportionately non-white, both known risk factors for inferior survival after pediatric HT 16 the late survival difference persisted after controlling for these. Potentially, greater medical/surgical complexity or accrued pre-HT comorbidities for heterotaxy/situs anomaly recipients persist after HT and influences late survival but was not captured in our analysis. Though we found no significant differences in prior sternotomies between the groups, these data do not convey number, timing, or complexity of cardiac surgeries prior to HT. Similarly, although we found no difference in time-to-event for common causes of late post-HT mortality (ie, rejection, infection, PTLD, and CAV), we lack details about severity of these events.
Rejection associated with hemodynamic compromise imparts significantly higher risk of death than rejection without hemodynamic compromise. 17, 18 Likewise, PTLD and CAV severity influence survival. 19, 20 The broad, multisystem involvement of heterotaxy syndrome, 21 including the potential for overwhelming bacterial sepsis with asplenia/functional asplenia, may also contribute to the observed survival difference. In a recently reported neonatal heterotaxy syndrome cohort, extracardiac causes were implicated in 18% of deaths. 22 
Perioperative Morbidities
The primary strength of our analysis is the ability to identify and analyze patients with heterotaxy and other complex arrangements of cardiac situs in a large, multicenter cohort, thereby providing novel insights into post-HT survival, perioperative complications, procedures, and resource utilization. We hypothesized that HT recipients with heterotaxy/situs anomaly have worse perioperative outcomes due to increased surgical complexity related to anomalies of cardiac position and venous return. 4, [23] [24] [25] [26] Indeed, we have found evidence of this. Despite shorter procurement distances, adjusted ischemic time was 19 minutes more in the heterotaxy/ situs anomaly group, suggesting greater surgical complexity and longer cardiopulmonary bypass durations. Increases in ischemic and bypass times in heterotaxy have been reported by others, 5 and both are risk factors for mortality in children undergoing cardiac surgery.
14,27 Also consistent with our hypothesized increased surgical complexity, we found that patients with heterotaxy/situs anomaly who were transplant recipients underwent cardiac reoperation about twice as frequently as nonheterotaxy/situs anomaly CHD recipients, and more commonly underwent cardiac catheterization and peripheral vascular stent placement before discharge from the HT hospitalization. Unfortunately, we do not know the indications for reoperations, catheterizations, or vascular stent placements to further characterize these events. Infection, renal failure requiring dialysis, and longer duration of mechanical ventilation were also more common postoperatively in heterotaxy/situs anomaly recipients. However, the occurrence of 1 may contribute to the need for another (eg, renal failure leading to volume overload contributing to prolonged mechanical ventilation.) Unfortunately, we cannot disentangle these associations in our dataset. Although asplenia predisposes to bacteremia/sepsis, 28 we found no differences in the presence of ICD-coded encapsulated bacterial infections between the groups. This may be due to relatively short observation, analysis of both asplenic and polysplenic patients in the heterotaxy/ situs anomaly group (which cannot be unbundled with ICD-9 coding), inability to identify causative organisms, or insufficient coding. Heterotaxy has been associated with prolonged mechanical ventilation and tracheostomy after cardiac surgery, 29 which has been attributed to increased prevalence of ciliary dyskinesia. 30 Although ciliary dyskinesia has been implicated in polycystic kidney disease, 31 and heterotaxy syndrome is associated with genitourinary anomalies, we found no reports of predisposition toward renal failure in heterotaxy. Given that longer bypass times are independently associated with kidney injury in adults undergoing HT 32 and children undergoing surgery for CHD, [32] [33] [34] a relationship between these in heterotaxy/ situs anomaly recipients is feasible.
LOS and Costs
It is not surprising that post-HT LOS and costs were greater for heterotaxy/situs anomaly recipients given the increased complications observed. These increases are similar to what has been reported for pediatric HT recipients with other complicating features, such as requirement for mechanical circulatory support 35 or allosensitization, 36 and in whom HT is commonly performed. Therefore, on the basis of increased LOS and costs alone, children with heterotaxy/situs anomaly should not be excluded from transplant consideration.
Limitations
Our analysis has many limitations. Our definition of heterotaxy/situs anomaly relied on ICD codes, which can be ambiguous. Errors and incomplete coding may also exist. ICD codes do not allow us to distinguish between leftand right-isomerism, making our population clinically heterogeneous. Furthermore, heterotaxy can be difficult to categorize, even with access to more detailed anatomic information than was available. 37 However, the racial distribution of our heterotaxy/situs anomaly cohort mirrors other reports of increased prevalence in AfricanAmerican, Asian, and Hispanic individuals. [38] [39] [40] [41] Furthermore, our heterotaxy/situs anomaly cohort is enriched for diagnoses common in heterotaxy (eg, anomalous pulmonary and systemic venous return, pulmonary outflow anomalies, and congenital heart block). These observations support the validity of our cohort. Still, it is likely that some nonheterotaxy recipients in our primary analysis were misclassified, particularly those who met criteria based on having the ICD-9 diagnosis codes of dextrocardia and/or situs inversus without polysplenia. These codes may have been applied when the heart alone was malpositioned or in patients with situs inversus totalis. However, this would only diminish the differences between the groups. Also, when we included only patients with ICD codes for asplenia/polysplenia in sensitivity analysis, the survival difference remained.
Other potential limitations are our model selection techniques and validity of the control group. Although we utilized data-driven model selection to identify relevant covariates for the regression models, some potentially important variables (eg, age and prior univentricular repair) did not meet inclusion criteria. However, when we locked these clinically relevant covariates into the multivariable model, we still observed increased mortality of heterotaxy/situs anomaly recipients. Further, when we controlled for possible selection bias through propensity score matching, the survival difference remained. These sensitivity analyses suggest that our conclusions are robust, adding strength to our findings.
Because our sample is limited only to HT recipients at PHIS-member hospitals, primarily children and young adults, our findings should not be generalized to adults. Also, because PHIS does not capture outpatient encounters or track patients across hospitals, our analysis of postdischarge complications is limited to those reported at yearly intervals in the SRTR. The Pediatric Heart Transplant Study 42 dataset collects greater detail on some of these events and thus may be a good choice for linkage to PHIS to further explore associations of postdischarge infection, rejection, PTLD, and CAV on late survival in heterotaxy syndrome. Ideally, a dataset that contains a more granular focus on heterotaxy could verify our findings, particularly some of the less-expected findings, such as prolonged mechanical ventilation or renal failure.
CONCLUSIONS
In a population-based analysis of administrative data on pediatric HT recipients with heterotaxy and other complex arrangements of cardiac situs we observed increased mortality, longer LOS, and greater costs of care from HT surgery to discharge relative to other nonheterotaxy/situs anomaly HT recipients with CHD ( Figure 3) . Early mortality and resource use differences could be explained by increased early postoperative complications, including more frequent cardiac reoperations and vascular stenting; however, the reason(s) for the difference in late survival is unclear. Further study is warranted.
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Survival
FIGURE E2. Sensitivity analysis of survival for patients with heterotaxy/ situs anomaly compared with a propensity score-matched group of nonheterotaxy/situs anomaly patients with congenital heart disease (CHD). Univariable Kaplan-Meier estimator showing that patients with heterotaxy/ situs anomaly (red) have inferior survival after heart transplantation compared with a propensity score-matched group of patients with CHD in the absence of heterotaxy (blue). There is a survival difference after transplant between the propensity score-matched groups. Propensity score matching was performed to address the potential for bias from inadequate/ incomplete selection of regression model covariates in our primary survival analysis ( Figure 1 ). Dotted lines depict 95% confidence intervals and the numbers at risk in each group are shown beneath the graph. . Sensitivity analysis of survival after heart transplant for patients meeting stricter inclusion criteria for heterotaxy. Univariable KaplanMeier analysis of survival after heart transplantation, using stricter inclusion criteria, defined as International Classification of Diseases code for polysplenia/asplenia only, to delineate heterotaxy recipients (red, poly-/asplenia) shows decreased survival compared with patients with congenital heart disease (CHD) in the absence of heterotaxy (blue, nonpoly-/aolysplenia CHD). This analysis shows a survival difference after transplant between the groups using this stricter definition of heterotaxy. Dotted lines depict 95% confidence intervals and the numbers at risk in each group are shown beneath the graph. Values are presented as n (%). Ordered from greatest to least absolute risk difference. Positive absolute risk difference favors heterotaxy group, negative favors nonheterotaxy CHD. Only ICD codes with P value <.1 are shown. ICD, International Classification of Diseases; CHD, congenital heart disease. *ICD-10 codes were translated to ICD-9 per Table E1 . yICD codes only available for 1199 of 1254 patients in the nonheterotaxy CHD group, 177 of 186 in the heterotaxy group. zFisher exact test. Costs are in adjusted to 2016 inflation, presented as median cost (interquartile range). Other costs constitutes predominately rooming and nursing charges. CHD, Congenital heart disease; HT, heart transplant. Costs are adjusted to 2016 inflation, presented as median cost (interquartile range). Other costs constitutes predominately rooming and nursing charges. CHD, Congenital heart disease; HT, heart transplant.
